BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer ProductsBenzinga • 08/05/24
BioNTech's stock slides 4% after earnings fall short of estimates as COVID vaccine falls slideMarket Watch • 08/05/24
BioNTech Announces Second Quarter 2024 Financial Results and Corporate UpdateGlobeNewsWire • 08/05/24
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced MelanomaGlobeNewsWire • 07/30/24
Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA TherapeuticsBusiness Wire • 07/23/24
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024GlobeNewsWire • 07/22/24
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European UnionBusiness Wire • 06/27/24
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate CancerGlobeNewsWire • 06/24/24
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)Business Wire • 06/01/24
BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine EcosystemGlobeNewsWire • 05/29/24
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnershipPRNewsWire • 05/27/24
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024GlobeNewsWire • 05/21/24
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced TermGlobeNewsWire • 05/21/24
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024GlobeNewsWire • 05/17/24